Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast add-on therapy for persistent pemphigus vulgaris
IRCT20241002063241N1Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apremilast in pemphigus vulgaris (PV), sponsored by Tehran University of Medical Sciences. Primary endpoints: Pemphigus Disease Area Index change, Lesion size change and 4 more. Started Nov 2024; status: completed.
02
Drugs
apremilast
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on IRCT20241002063241N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241002063241N1.